Field Medical to Present at Industry-Leading Conference
A healthcare milestone is on the horizon as Field Medical Inc., a prominent clinical-stage medical technology firm, prepares for a key presentation at an esteemed healthcare event. Founded with the vision of revolutionizing cardiac treatment, Field Medical is set to unveil insights into its groundbreaking next-generation pulsed field ablation (PFA) platform.
Overview of the Presentation
Steven Mickelsen, MD, the founder of Field Medical, will be taking the stage to present at the upcoming annual J.P. Morgan Healthcare Conference, which is renowned for bringing together industry leaders on January 15. This year, attendees can look forward to an extensive overview of the FieldForce™ PFA system, which aims to support treatments for ventricular tachycardia (VT) and atrial fibrillation (AF).
Key Highlights of the Presentation
The presentation will delve into the various aspects of the company's innovative technologies, specifically focusing on the clinical advancements achieved in treating VT and providing updates on the Field-PULSE AF study. Additionally, there will be an outline of the strategic plans for the upcoming pivotal VT trial, which is crucial for the expansion of treatment options.
Networking and Meetings
Field Medical encourages interested parties attending the conference to connect with its leadership team for potential discussions about their pioneering approach in the medical technology space. The team will be available for meetings throughout the event, allowing for valuable interactions and sharing of ideas.
About Field Medical Inc.
Founded in 2022, Field Medical is dedicated to advancing solutions for complex cardiac arrhythmias using its innovative pulsed field ablation technology. The FieldForce™ Ablation System integrates a unique catheter design with proprietary FieldBending™ energy that facilitates optimal ablation procedures, ultimately striving to enhance patient outcomes in treating both ventricular and atrial arrhythmias.
Recently, the company has made considerable strides, receiving Breakthrough Device Designation and participating in the FDA TAP Pilot Program for its ventricular tachycardia indication. Notably, the VCAS trial has garnered attention, underscoring the effectiveness of their technologies.
Commitment to Innovation and Patient Care
At the core of Field Medical’s mission is an unwavering commitment to improving patient care through advanced medical technologies. Their goal is to provide comprehensive solutions that address the complexities of cardiac treatments, making strides that could redefine patient experiences.
To learn more about Field Medical and its initiatives, interested individuals are encouraged to visit their official website and view their latest updates across various platforms including LinkedIn.
Frequently Asked Questions
What is the purpose of Field Medical's presentation at the conference?
The presentation aims to provide insights into the company’s innovative technologies, especially the FieldForce™ PFA platform for treating ventricular tachycardia and atrial fibrillation.
Who will be presenting for Field Medical?
Dr. Steven Mickelsen, the founder of Field Medical, will be the keynote speaker during this important event.
What recent achievements has Field Medical accomplished?
Field Medical has achieved Breakthrough Device Designation and has entered the FDA TAP Pilot Program for its ventricular tachycardia indication.
How can individuals contact Field Medical for meetings during the conference?
Those interested in setting up meetings can reach out through designated contacts provided during the conference.
Where can I find more information about Field Medical?
More details about the company and its technologies can be found on their official website and through their social media channels.
